Febrile neutropenia is having a fever of ≥38.3 ºC or ≥38 ºC over an hour and neutropenia that is having an absolute neutrophil count (ANC) of <500 neutrophils/mm3 or an ANC <1000 neutrophils/mm3 expected to decline to ≤500 neutrophils/mm3 over the next 48 hours.
The risk of febrile neutropenia is directly proportional to the duration and severity of neutropenia.
Fever is frequently the only indication of infection in the neutropenic patient.
  1. Brown CH. Febrile neutropenia infections. US Pharm. 2013;38(5)(Oncology Suppl):3-7. Accessed 05 Sep 2013
  2. De Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010 May;21(Suppl 5):v252-v256. doi: 10.1093/annonc/mdq196. PMID: 20555092
  3. D’Antonio D, di Girolamo A, Iacone A, et al. Evaluation of azlocillin-amikacin combination for empirical therapy of infection in febrile neutropenic patients. J Chemother. 1989 Dec;1(6):407-412. PMID: 2693624
  4. DePauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. Ann Intern Med. 1994 May;120(10):834-844. PMID: 8154643
  5. Fishman A, Chowers M, Altaras M, et al. Aztreonam plus piperacillin-empiric treatment of neutropenic fever in gynecology-oncology patients receiving cisplastin-based chemotherapy. Eur J Gynaecol Oncol. 1998;19(2):126-129. PMID: 9611050
  6. Freifeld A, Marchigiani D, Walsh T, et al. A double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999 Jul;341(5):305-311. PMID: 10423464
  7. Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 Feb;52(4):e56-e93. doi: 10.1093/cid/cir073. PMID: 21258094
  8. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002 Mar;34(6):730-751. PMID: 11850858
  9. Infectious Diseases Society of Taiwan, Hematology Society of Taiwan, Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsien for the Infectious Diseases Research and Education, CY Lee’s Research Foundation for Pediatric. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect. 2005 Dec;38(6):455-457. PMID: 16341349
  10. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemein. Ann Hematol. 2003 Oct;82(Suppl 2):S105-S117. PMID: 13680173
  11. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med. 1999 Jul;341(5):312-318. PMID: 10423465
  12. Jun HX, Zhixiang S, Chun W, et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents. 2005 Dec;26(Suppl 2):S128-S132. PMID: 16253480
  13. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004 Sep;351(14):1391-1402. PMID: 15459300
  14. Peacock JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients: a randomized, double-blind trial. Ann Intern Med. 2002 Jul;137(2):77-86. PMID: 12118962
  15. Mortimer J, Miller S, Black D, et al. Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients. Am J Med. 1998 Jul;85:17-20. PMID: 3400679
  16. MedWormhttp://www.medworm.com/rss/index.php/Cancer-%26-Oncology/6/http://www.medworm.com/rss/medicalfeeds/specialities/Cancer-Oncology.xml
  17. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  18. NCCN Fever and Neutropenia Panel Members. Fever and neutropenia. Version 1.2004. NCCN practice guidelines in oncology - v.1.2004. http://www.nccn.org/professionals/physician_gls/PDF/fever.pdf.Peacock. 2004
  19. Ahmed NM. Management of fever in children with non- chemotherapy-induced neutropenia. UpToDate. http://www.uptodate.com/contents/management-of-fever-in-children-with-non-chemotherapy-induced-neutropenia?source=search_result&selectedTitle=1~150. Sep 2010. Accessed 14 Feb 2011
  20. Robbins GK. Fever in the neutropenic adult patient with cancer. UpToDate. http://www.uptodate.com/contents/fever-in-the-neutropenic-adult-patient-with-cancer?source=. Sep 2010. Accessed 14 Feb 2011
  21. Bertuch AA. Fever in children with chemotherapy-induced neutropenia. UpToDate. http://www.uptodate.com/contents/fever-in-children-with-chemotherapy-induced-neutropenia?source=search_result&selectedTitle=2~150.Sep. Sep 2010. Accessed 14 Feb 2011
  22. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. NCCN Practice guidelines in oncology - v.2.2009. http://www.oralcancerfoundation.org/treatment/pdf/infections-NCCN.pdf. Accessed 16 Feb 2011
  23. National Comprehensive Cancer Network Myeloid Growth Factors Panel Members. Myeloid growth factors. NCCN Practice guidelines in oncology - v.1.2010. http://jhasioncolog.com/fn2010/eresourcecenter/pdfs/NCCN%20myeloid_growth%20factor%20guidelines.%20v1.2010.pdf. 2010. Accessed 16 Feb 2011
  24. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: European Society for Medical Oncology (ESMO) clinical practice guidelines. Ann Oncol. 2016 Sep;27(Suppl 5):v111-v118. doi: 10.1093/annonc/mdw325. PMID: 27664247
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
31 Oct 2017
In patients with underlying heart failure (HF) or chronic obstructive pulmonary disease (COPD), concurrent episodes of community-acquired pneumonia increase the risk of disease exacerbations, such as short-term cardiac complications and respiratory failure, a recent study has shown.
16 Mar 2017
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coli and Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6
02 Nov 2017
Passive immunization with neutralizing antibodies (nAbs) do not appear to prevent transmission of HIV-1 to the infant from the infected mother’s breastmilk, a recent study suggests.